DSM-Firmenich AG (XSWX:DSFIR) Research & Development: CHF0 Mil (TTM As of Dec. 2025)


XSWX:DSFIR DSM-Firmenich AG XSWX:DSFIR
31 GF Score
Price CHF74.82
GF Value CHF70.59
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is DSM-Firmenich AG Research & Development?

DSM-Firmenich AG XSWX:DSFIR +5.62% 31 Research & Development is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:DSFIR with a GF Score™ of 31/100 and a GF Value™ of CHF70.59 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. DSM-Firmenich AG's Research & Development for the six months ended in Dec. 2025 was CHF0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0 Mil.

DSM-Firmenich AG  (XSWX:DSFIR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DSM-Firmenich AG Research & Development Related Terms

DSM-Firmenich AG Research & Development Historical Data

* Premium members only.

The historical data trend for DSM-Firmenich AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DSM-Firmenich AG Research & Development Chart

DSM-Firmenich AG Annual Data
Trend Dec21 Dec23 Dec24 Dec25
Research & Development
747.21 614.89 759.96 665.33

DSM-Firmenich AG Semi-Annual Data
Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XSWX:DSFIR
31GF Score
DSM-Firmenich AG XSWX:DSFIR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DSM-Firmenich AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF0 Mil mean?
DSM-Firmenich AG (XSWX:DSFIR) has a Research & Development of CHF0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on DSM-Firmenich AG and its competitors.
Is DSM-Firmenich AG's Research & Development too high?
DSM-Firmenich AG's current Research & Development is CHF0 Mil. Overall, DSM-Firmenich AG has a GF Score™ of 31/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DSM-Firmenich AG's Research & Development compare to LIN and SHW?
DSM-Firmenich AG's Research & Development of CHF0 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Chemicals company?
A good Research & Development depends on the Chemicals industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on DSM-Firmenich AG and its competitors. DSM-Firmenich AG's current Research & Development is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DSM-Firmenich AG stock overvalued right now?
Based on GuruFocus' analysis, DSM-Firmenich AG (XSWX:DSFIR) is currently considered Fairly Valued. The stock's GF Value™ is CHF70.59, compared to a current price of CHF74.82 — trading 6% above its estimated fair value. The current Research & Development is CHF0 Mil. DSM-Firmenich AG's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For DSM-Firmenich AG (XSWX:DSFIR), the current Research & Development is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DSM-Firmenich AG (XSWX:DSFIR) Overvalued in 2026?

Based on GuruFocus' analysis, DSM-Firmenich AG stock appears to be overvalued. The current stock price of CHF74.82 is trading 6% above its estimated GF Value™ of CHF70.59. GuruFocus considers DSM-Firmenich AG to be Fairly Valued.

Key valuation signals for XSWX:DSFIR:

  • Research & Development: CHF0 Mil
  • GF Value™: CHF70.59 vs. price of CHF74.82 (6% above fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the XSWX:DSFIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DSM-Firmenich AG Business Description

Address Wurmisweg 576, Kaiseraugst, CHE, 4303
DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.
31GF Score

Get the complete analysis for XSWX:DSFIR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF74.82
Price
CHF70.59
GF Value